Prosecution Insights
Prosecution Insights
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (43%) |
| §102 only | 1 (14%) |
| No statute on record | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 1 | 57.5% | +64.7% |
| METCALF, MATTHEW CURRAN | 1 | 100.0% | +0.0% |
| FAUST, AMBER KATHLEEN | 1 | 62.3% | +50.3% |
| ZARA, JANE J | 1 | 70.8% | +15.9% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.3% | +42.1% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 67.7% | +39.0% |
| CLARKE, TRENT R | 1 | 41.2% | +26.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 126d overdue |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | VIJAYARAGHAVAN, JAGAMYA NMN | 80d overdue |
| 17934799 | HIGH PURITY gRNA SYNTHESIS PROCESS | ZARA, JANE J | 30d overdue |
| 16488149 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)-RELATED DISORDERS | CLARKE, TRENT R | 1d overdue |
| 18444368 | COMPOSITIONS AND METHODS FOR GENE EDITING | HOLLAND, PAUL J | 33d |
| 18179201 | MULTIPLEX GENE EDITED CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY | FAUST, AMBER KATHLEEN | 40d |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1647 | 1 |
| 1643 | 1 |
| 1637 | 1 |
| 1645 | 1 |
| 1633 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18444368 | COMPOSITIONS AND METHODS FOR GENE EDITING | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | 33d | Pending | Feb 16, 2024 |
| 18188406 | ANTI-CD83 CAR-T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION | METCALF, MATTHEW CURRAN | 1647 | Other | Non-Final OA | 60d overdue | Pending | Mar 22, 2023 |
| 18179201 | MULTIPLEX GENE EDITED CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY | FAUST, AMBER KATHLEEN | 1643 | Other | Final Rejection | 40d | Pending | Mar 06, 2023 |
| 17934799 | HIGH PURITY gRNA SYNTHESIS PROCESS | ZARA, JANE J | 1637 | §103 | Final Rejection | 30d overdue | Pending | Sep 23, 2022 |
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 1645 | §103 | Non-Final OA | 126d overdue | Pending | Sep 15, 2022 |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | Other | Final Rejection | 80d overdue | Pending | Oct 01, 2021 |
| 16488149 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)-RELATED DISORDERS | CLARKE, TRENT R | 1651 | §102 | Final Rejection | 1d overdue | Pending | Aug 22, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial